Epilepsy and seizures affect at least 2.3 million individuals in the United States. Although antiepileptic drugs (AEDs) are the primary form of treatment, recent outcome surveys reveal only mixed success even with the new AEDs that have become available over the past decade. Approximately one-third of patients have seizures that are unresponsive to pharmacological therapy [1,2] (Figure 12.1). In addition, safety and tolerability issues associated with both the acute and chronic side effects and toxicity complications further diminish the effectiveness of AEDs. Non-adherence to AEDs, which is highly prevalent in the epilepsy population, also diminishes treatment effectiveness and further increases mortality as well as significantly increasing healthcare utilization [3]. Children and adolescents with uncontrolled seizures continue to carry a sad burden of higher mortality rates, higher rates of accidents and injuries, greater incidence of cognitive and psychiatric impairment, poor self-esteem, higher levels of anxiety and depression, and greater social stigmatization or isolation compared with the non-epileptic population. The shortcomings of AEDs in improving overall outcome highlight the need for other treatments (Figures 12.2 and 12.3). Other treatment options are available for select subgroups of patients, including the ketogenic Epilepsy in Children and Adolescents, First Edition. Edited by James W. Wheless.